Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q4 FY2025 Earnings Presentation
19 slides from Ngl Fine-chem's earnings presentation, May 23, 2025
Slide 1: Exchange filing letter: Investor Presentation for quarter and year ended March 31, 2025
O NGL Fine-Chem Limited Regd. Office 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@naffinechem.com CIN’ L24110MH1981PLC025884, Website www.ngffinechem.com May 23, 2025 To, Listing Department, Listing De
Slide 2: NGL Fine-Chem Limited Investor Presentation
ONGL Fine-Chem Ltd NGL Fine-Chem Limited INVESTOR PRESENTATION
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 4: Inside This Presentation
Inside This Presentation Pg. No. Pg. No. 04 11 Q4 & FY25 Overview, Highlights Key Strengths and Strategy ° ‘ Pg. No. Historical Financial Performance
Slide 5: Q4 & FY25 Highlights
01 Q4 & FY25 Highlights 05 MANAGEMENT COMMENTARY 06 QUARTERLY OPERATIONAL METRICS 07 FULL YEAR OPERATIONAL METRICS 08 SUMMARY OF PROFIT AND LOSS STATEMENT 09 SUMMARY OF BALANCE SHEET 10 SUMMARY OF CASH FLOW STATEMENT
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, The operating environment in Q4 FY25 remained Validation batches are underway, and we have challenging, in line with our previous guidance. initiated the data gathering and filing process Demand across our product portfolio continued as part of our regulatory
Slide 7: Quarterly Operational Metrics
Quarterly Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION ANIMAL API 90% 93% 20% TOP 3 PRODUCTS 34% 37% 33% HUMAN AP 3% 2% X TOP 5 PRODUCTS 49% 50% 50% INTERMEDIATES 3% 2% 1% TOP 10 PRODUCTS 72% 72% 72% FORMULATIONS 2% 3% 2% GEOGRAPHIC MIX CUSTOMER CONCENTRATION Asia 42% 39% S TOP 3
Slide 8: Full Year Operational Metrics
Full Year Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION ANIMAL API 83% 89% 22% TOP 3 PRODUCTS 34% 32% 34% HUMAN AP 5% 3% xS TOP 5 PRODUCTS 47% 6% 49% INTERMEDIATES 7% 3% 2% TOP 10 PRODUCTS 72% 61% 69% FORMULATIONS 5% 5% 2% GEOGRAPHIC MIX CUSTOMER CONCENTRATION Asia 34% 34% EDES TOP
Slide 9: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement T IN CRORES CemTcums REVENUE FROM OPERATIONS o 99.76 awes o 89.10 94.97 Gea Yoy M 6.59% -4.80% 33868 R368.26 oy 8.73% OTHER INCOME 3.68 013 -0.97 632.07% -126.24% 1413 8.63 -38.91% TOTAL INCOME 103.44 88.97 94.01 5.66% -9.12% 352.81 376.89 6.82% TOTAL OPERATING E
Slide 10: Summary of Balance Sheet
Summary of Balance Sheet T IN CRORES SHAREHOLDERS FUND 262.63 282.43 NON CURRENT LIABILITIES 6.32 31.99 LONG TERM BORROWINGS 0.74 25.34 CURRENT LIABILITIES 86.59 118.97 SHORT TERM BORROWINGS 31.70 47.82 TOTAL EQUITY AND LIABILITIES 355.54 433.39 NON CURRENT ASSETS 142.87 198.01 NET BLOCK 85.30 142.1
Slide 11: Summary of Cash Flow Statement
Summary of Cash Flow Statement T IN CRORES CASH FLOW FROM OPERATING ACTIVITIES 20.47 35.82 CASH FLOW FROM INVESTING ACTIVITIES (26.82) (34.55) CASH FLOW FROM FINANCING ACTIVITIES (1.08) (1.08) NET CASH FLOW (7.43) 0.19 CASH AT THE BEGINNING OF YEAR 7.83 0.40 CASH AT THE END OF YEAR 0.40 0.58 010 NGL
Slide 12: Overview, Strengths and Strategy
02 QOverview, Strengths and Strategy 12 LEADING ANIMAL HEALTH COMPANY 13 LEADERSHIP IN VETERINARY APl SEGMENT 14 STATE-OF-THE-ART MANUFACTURING CAPABILITIES 15 STRATEGY FOR NEXT LEG OF GROWTH
Slide 13: Leading Animal Health Company
~ Leading Animal Health Compan \‘1 yL) L COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS * 39 APIs (37 Veterinary + Market leadership in + 3 state of the art = Strong presence * ~404 customers API
Slide 14: Leadership in Veterinary API Segment
Leadership in Veterinary APl Segme ot ) N REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with APl SEGMENT 1 27 CONCENTRATION 95% in-house manufacturing and (R IN CRORES) CAGRD (OF SALES FY25) backward integrated facilities leading to cost competitiveness FY25 327 Fr24 | ] 30
Slide 15: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabiliti9 HIGHLIGHTS 3 manufacturing facilities 10'000"‘2 102 m? 194 m? located at Tarapur & Navi Maharashtra, VANUFACTURING AREA OF NPy GLASS-LINED STAINLESS STAINLESS STEEL Mumbai, designed to meet the FACILITIES requirements of regulatory agencies and are capable
Slide 16: Strategy for next leg of growth
. ~ Strategy for next leg of grow .0.-0. (BROWNFIELD EXPANSION) < éA + Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE + Additional capacities of CAPACITIES TO MEET intermediates GROWING DEMAND + Commercial production started ( GREENFIELD EXPANSION AT TARAPUR ) « Capacity
Slide 17: Historical Financial Performance
03 Historical Financial Performance 17 ROBUST FINANCIAL PERFORMANCE
Slide 18: Robust Financial Performance
Robust Financial Performana REVENUE EBITDA PAT (T IN CRORES) (T IN CRORES) (Z IN CRORES) Fr25 I 368 Fr2s I 34 Fy24 I 21 F24 [ ] 339 Fe4 53 A — Y| Fve3 1278 Fve3 134 23 121 Free [ ""7318 Freea [ ""768 Fr22 | ] 50 21 7258 21 [ ] 80 Fy21 ] 57 GROSS MARGIN EBITDA MARGIN PAT MARGIN (IN %) (IN %) (IN %) F
Slide 19: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Pallavi Pednekar Abhishek Mehra Thank You NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 ONGL Fine-Chem Ltd Corporate Office 301, E-square, Subhash Road, Vile Parle (East),